Sodium-glucose linked transporter 2 inhibitors (SGLT2s) and alanine aminotransferase levels (ALT) in the Associated of British Clinical Diabetologists (ABCD) audits

被引：0
|
作者：
Gallen, I. [1 ]
Crabtree, T. S. J. [2 ,3 ]
Gallagher, A. [4 ]
Dhatariya, K. [5 ]
Bickerton, A. [6 ]
Elliott, J. [7 ]
Rayman, G. [8 ]
Ryder, R. E. J. [2 ]
机构：
[1] Royal Berkshire NHS Fdn Trust, Reading, Berks, England
[2] Sandwell & West Birmingham Hosp NHS Trust, Birmingham, W Midlands, England
[3] Univ Nottingham, Nottingham, England
[4] Univ Hosp Leicester NHS Trust, Leicester, Leics, England
[5] Norfolk & Norwich Univ Hosp NHS Trust, Norwich, Norfolk, England
[6] Yeovil Dist Hosp NHS Trust, Yeovil, England
[7] Sheffield Teaching Hosp NHS Trust, Sheffield, S Yorkshire, England
[8] East Suffolk & North Essex NHS Trust, Ipswich, Suffolk, England
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
424
引用
收藏
页码：218 / 218
页数：1
相关论文
共 50 条
  • [21] Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use
    Siafarikas, Christos
    Kapelios, Chris J.
    Papatheodoridi, Margarita
    Vlachogiannakos, John
    Tentolouris, Nikolaos
    Papatheodoridis, George
    LIVER INTERNATIONAL, 2024, 44 (04) : 884 - 893
  • [22] Sodium-glucose co-transporter-2 (SGLT2) inhibitors: novel oral antidiabetic drugs
    Przybyslawski, Blazej
    Karbowiak, Piotr
    Rzeszotarski, Jacek
    Walasek, Lech
    CLINICAL DIABETOLOGY, 2013, 2 (05): : 191 - 197
  • [23] Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients
    Song, Chelsey Chenxi
    Brown, Andrew
    Winstead, Ryan
    Yakubu, Idris
    Demehin, Moses
    Kumar, Dhiren
    Gupta, Gaurav
    ENDOCRINOLOGY DIABETES & METABOLISM, 2021, 4 (02)
  • [24] Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice
    Dutta, Deep
    Kalra, Sanjay
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2014, 64 (10) : 1203 - 1206
  • [25] Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide
    Simes, Bryce C.
    MacGregor, Gordon G.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2125 - 2136
  • [26] Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
    Gilbert, Richard E.
    KIDNEY INTERNATIONAL, 2014, 86 (04) : 693 - 700
  • [27] Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation
    Werkman, Nikki C. C.
    Nielen, Johannes T. H.
    van den Bergh, Joop P. W.
    Ejskjaer, Niels
    Roikjer, Johan
    Schaper, Nicolaas C.
    Rossi, Bernardette
    Klungel, Olaf
    Vestergaard, Peter
    de Vries, Frank
    Driessen, Johanna H. M.
    CURRENT DRUG SAFETY, 2021, 16 (01) : 62 - 72
  • [28] Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!
    Katsiki, Niki
    Rizzo, Manfredi
    Mikhailidis, Dimitri P.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023, 37 (07)
  • [29] Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review
    Kristy T. K. Lau
    Lui Ng
    Jason W. H. Wong
    Herbert H. F. Loong
    Wendy W. L. Chan
    Chi Ho Lee
    Carlos K. H. Wong
    Reviews in Endocrine and Metabolic Disorders, 2021, 22 : 1121 - 1136
  • [30] Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment - A Review
    Lau, Kristy T. K.
    Ng, Lui
    Wong, Jason W. H.
    Loong, Herbert H. F.
    Chan, Wendy W. L.
    Lee, Chi Ho
    Wong, Carlos K. H.
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2021, 22 (04): : 1121 - 1136
12345